Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Seattle Children's Hospital
Simcha IL-18, Inc.
Evopoint Biosciences Inc.
Kineta Inc.
Genocea Biosciences, Inc.
MultiVir, Inc.